NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
äŒæ¥ã³ãŒãNURO
äŒç€ŸåNeuroMetrix Inc
äžå Žæ¥Jul 22, 2004
æé«çµå¶è²¬ä»»è
ãCEOãDr. Shai N. Gozani, M.D., Ph.D.
åŸæ¥å¡æ°13
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 22
æ¬ç€Ÿæåšå°1000 Winter Street
éœåžWALTHAM
蚌åžååŒæNASDAQ Capital Market Consolidated
åœUnited States of America
éµäŸ¿çªå·02451
é»è©±çªå·17818909989
ãŠã§ããµã€ãhttps://www.neurometrix.com/
äŒæ¥ã³ãŒãNURO
äžå Žæ¥Jul 22, 2004
æé«çµå¶è²¬ä»»è
ãCEOãDr. Shai N. Gozani, M.D., Ph.D.
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã